Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of Lutetium Lu 177 JH020002 Injection in adult patients with advanced prostate cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyzna w wieku co najmniej 18 lat
- •Potwierdzony rozpoznaniem raka gruczołowego prostaty
- •Bardzo niski poziom testosteronu we krwi (poniżej 50 ng/dl)
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (ECOG 0-2)
- •Oczekiwana długość życia ponad 6 miesięcy
- •Dobrowolna zgodę na uczestnictwo w badaniu
✗ Disqualifies
- •Inne nowotwory (oprócz zmian skórnych lub pęcherza leczonych ponad 3 lata temu)
- •Przerzuty raka do mózgu z objawami lub wymagające leczenia
- •Leczenie innymi radioaktywnymi lekami w ciągu ostatnich 6 miesięcy
- •Wcześniejsza terapia PSMA (rodzaj terapii celowanej na raka prostaty)
- •Radioterapia prostaty w ciągu ostatnich 4 tygodni
- •Chemioterapia lub inne leki przeciwnowotworowe w ciągu ostatnich 4 tygodni
- •Uczestnictwo w innym badaniu klinicznym w ostatnich 4 tygodniach
- •Uczulenie na składniki leku
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 9, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (13)
Anhui Provincial Hospital
Hefei, China
Peking University First Hospital
Beijing, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, China
Sun Yat-Sen University Cancer Center
Guangzhou, China
Henan Cancer Hospital
Zhengzhou, China
Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital
Wuhan, China
The First Affiliated Hospital of Soochow University
Suzhou, China
Affiliated Hospital of Jiangsu University
Wuxi, China
Shandong Cancer Hospital
Jinan, China
Fudan University Shanghai Cancer Center
Shanghai, China
West China Hospital of Sichuan University
Chengdu, China
Tianjin Cancer Hospital Airport Hospital
Tianjin, China
Zhejiang Provincial People's Hospital
Hangzhou, China
Trial contact
Bivision Pharmaceuticals, Inc.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.